Knowledge@wharton

When Roche Holding acquired full ownership of Genentech last year the $46.8 billion deal was the culmination of a more than 20-year relationship between the Swiss pharmaceutical giant and the Silicon Valley biotechnology company. In a recent presentation at Wharton San Francisco Steve Krognes -- a former Roche executive who is now senior vice president and CFO of Genentech -- talked about the pharma company’s decision to pursue the merger efforts to raise capital amid the beginnings of the 2008 recession and the aftermath of the deal. See acast.com/privacy for privacy and opt-out information.